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Rhabdomyosarcoma is a rare tumor, with an annual incidence of 4 in 1 million population. Around 400 cases are diagnosed among 0-to 19- year-olds in Europe each year, 1 50-60 of them in Italy. 2, 3 It is nonetheless the most common soft tissue sarcoma in children and adolescents. This highly malignant tumor has a strong propensity to metastasize, but also a good chance of responding to conventional chemotherapy. Recent pediatric oncology studies report overall survival rates exceeding 70% for patients with localized rhabdomyosarcoma given risk-adapted multidisciplinary treatments, including surgery, radiotherapy, and multiagent chemotherapy in particular. 4 The outcome is unsatisfactory for some patient categories, however, such as adolescents and young adults with rhabdomyosarcoma, patients with an alveolar histology, and those with distant metastases or relapsing disease.
In September 2019, the European pediatric Soft Tissue Sarcoma Study Group (EpSSG) published the results of a rhabdomyosarcoma study (EpSSG RMS 2005) , particularly reporting on the efficacy of maintenance therapy. 5 When the study findings were presented at the plenary sessions of the congresses held by the American Society of Clinical Oncology in June 2018 and by the European Society of Paediatric Oncology in May 2019, the media described them as a "home run" for the treatment of rhabdomyosarcoma. Here we retrace the story of this important study to glean useful hints and explore what to do next in clinical research on rhabdomyosarcoma.
The phase III randomized EpSSG RMS 2005 trial was tailored to patients under 21 years old with localized rhabdomyosarcoma. The protocol paid special attention to the so-called high-risk patients, i.e., those with incompletely resected embryonal rhabdomyosarcoma arising at unfavorable sites and age ⩾10 years and/or tumor size >5 cm, any embryonal rhabdomyosarcoma with nodal involvement, or any alveolar rhabdomyosarcoma without nodal involvement. This high-risk group was believed to represent 55%-60% of all patients with localized rhabdomyosarcoma, whose 5-year event-free survival (EFS) and overall survival (OS) rates were estimated at around 50%-55% and 60%, respectively. For these patients, the protocol included 2 randomizations ( Figure 1 ). The first, applied at the time of diagnosis, was used to investigate whether patients with rhabdomyosarcoma might benefit from a higher doxorubicin dose intensity in the initial period of their treatment. The results were published in 2018: with 484 patients treated, the 3-year EFS rate was 63.3% for patients in the standard arm (ifosfamide, vincristine, and actinomycin-D; IVA), and 67.5% for those in the experimental arm (ifosfamide, vincristine and actinomycin-D plus doxorubicin; IVADo) (p = 0.33). The study showed that adding dose-intensified doxorubicin to the standard IVA chemotherapy did not significantly improve the outcome for patients with high-risk nonmetastatic rhabdomyosarcoma. Acute toxicity was significantly more common in the IVADo group. 5 The second randomization used in EpSSG RMS 2005 concerned maintenance therapy, and the results have been published recently. 6 The trial investigated whether treating patients for longer with a less intensive, but continuous chemotherapy regimen (maintenance therapy) could improve the outcome of those with high-risk rhabdomyosarcoma in complete remission at the end of the standard 9 courses of therapy ( Figure 1 ). This trial was prompted by the results of a small study conducted many years earlier (between 1998 and 2001) at the Istituto Nazionale dei Tumori in Milan on 33 patients with heavily treated, refractory sarcomas, who were given vinorelbine as a single-agent therapy-not based on any preclinical findings or promising previous data, but rather as a last effort to treat them. There was a somewhat unexpected good response rate among the patients with rhabdomyosarcoma: 6 partial responses out of 12 cases with measurable disease ( Table 1) . 7 Thus the physicians in Milan conducted another study, combining vinorelbine with cyclophosphamide (a drug known to be active in rhabdomyosarcoma), in an unusual, continuous low-dose oral administration. Vinorelbine and continuous low-dose metronomically administered cyclophosphamide were both believed to have particular antiangiogenic antitumor mechanisms that made this combination especially interesting. [8] [9] [10] [11] This second trial was conducted in Italy between 2002 and 2003, also seeking to establish the optimal dose of vinorelbine in this combination. It was seen as a pilot study for the maintenance therapy to use in the planned EpSSG study (a large European cooperation that was being developed at the time). The study confirmed the efficacy of vinorelbine (also in combination with cyclophosphamide), achieving 1 complete remission and 6 partial remissions among 17 heavily pretreated patients with rhabdomyosarcoma . 12 These 2 small trials in Milan paved the way to the use of a novel drug combination as maintenance therapy in the new EpSSG protocol. Although the data supporting the efficacy of vinorelbine and its combination with low-dose oral cyclophosphamide did not amount to much, even less was known for sure about the efficacy of a maintenance therapy for rhabdomyosarcoma. The German Cooperative Group had obtained some preliminary results suggesting that oral maintenance chemotherapy (trofosfamide plus etoposide or idarubicin) was more effective than high-dose chemotherapy with stem cell rescue after standard therapy in patients with metastatic disease, but theirs was not a randomized study and the treatment had been chosen at the physician's discretion. 13 Despite these shaky premises, the phase 3 EpSSG RMS 2005 randomized trial achieved a remarkable result. Between April 2006 and December 2016, 371 patients were randomized to either stop treatment or receive maintenance chemotherapy after induction IVA or IVADo therapy (plus surgery and/or radiotherapy). At the end of the study, it was clear that adding maintenance chemotherapy with vinorelbine and low-dose oral cyclophosphamide after standard treatment improved the survival of patients with high-risk, nonmetastatic rhabdomyosarcoma. Their 5-year OS rate was 86.5%, as opposed to 73.7% in the patients who stopped any treatment, a statistically significant difference (p = 0.009). 5 The difference in diseasefree survival rate (which was the primary endpoint of the trial) fell just short of the conventional definition of statistical significance (77.6% versus 69.8%, p = 0.06), but was statistically significant on per protocol analysis (77.8% versus 69.6%, p = 0.05). The analyses also showed that the maintenance therapy was more effective in some subgroups of patients than in others. 5 It is also worth mentioning that the acute toxicity of the new therapy was generally mild (neutropenia was the most common side effect, and some patients required drug dosage adjustments), though the risk of long-term toxicity (e.g., gonadal damage) warrants further monitoring.
It is noteworthy that the survival rates obtained in this group of patients in EpSSG RMS 2005 were higher than expected (when the protocol was planned, it was assumed that the 5-year EFS and OS rates would be around 50%-55% and 60%, respectively).
The longer survival achieved with the maintenance therapy is particularly important because this is the first randomized study to demonstrate a survival benefit from an experimental chemotherapy regimen in rhabdomyosarcoma in 30 years. Many randomized studies developed over the years have tried adding new drugs (such as cisplatin, melphalan, etoposide, doxorubicin, topotecan, and irinotecan) to the standard multiagent chemotherapy regimen (ifosfamide or cyclophosphamide plus vincristine and actinomycin-D), but-up until the EpSSG RMS 2005 trial on maintenance therapy-none of them succeeded in improving patient survival. [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] The results of EpSSG RMS 2005 change the rhabdomyosarcoma treatment paradigm. As Meyer put it in an editorial published by Lancet Oncology along with the EpSSG RMS 2005 findings, the evidence is simple: "vinorelbine plus low-dose cyclophosphamide maintenance chemotherapy cured more children and adolescents with rhabdomyosarcoma than standard treatment without maintenance chemotherapy" (and was well-tolerated as well). 25 This means that this kind of maintenance chemotherapy should be considered as the new standard for a certain type of rhabdomyosarcoma. In light of the results of EpSSG RMS 2005, the North American Children's Oncology Group (COG) investigators have amended their ongoing rhabdomyosarcoma trial (for "intermediate-risk" cases, which correspond to those described as "high risk"
in Europe) to include maintenance chemotherapy. That a very small empirical study conducted almost by chance in Milan could lead to a new therapy that is now used all over the world makes a good story. But where does it go from here? What else can we learn from this experience?
The main lesson here concerns the importance of international cooperation. In the preface to Rare Tumors in Children and Adolescents, we wrote: "If you work on frequent cancers, do randomized trials! If you work on rare cancers-find friends!" 26 Pediatric oncologists have always known that international cooperation is the way to go for a successful clinical trial on rare diseases-like cancer in childhood and adolescence. The EpSSG fully embraces this concept with a protocol that includes 14 countries (Argentina, Belgium, Brazil, Czech Republic, France, Ireland, Israel, Italy, Norway, Switzerland, Slovenia, Spain, the Netherlands, and the United Kingdom) and more than 100 centers enrolling patients. The Istituto Nazionale dei Tumori in Milan enrolled the largest number of cases. The efficacy of the EpSSG is further improved by its broad international collaborative links and high trial inclusion rate. In a previous study, the EpSSG reported that 77% of all children with rhabdomyosarcoma (age 0-14 years) and 64% of adolescents (15-19 years old) were enrolled in its trials. 27 These overall percentages are extremely satisfactory, and in some countries they were even higher (in Italy, for instance, they reached 96% and 84%, respectively).
There is another lesson that we can learn from our success story. As we strive to improve the outcome for patients with a poor prognosis, today's oncologists are making efforts to find novel therapeutic approaches involving molecular targets, immune treatments, and gene therapies. The treatment of rhabdomyosarcoma in children, and possibly of pediatric solid tumors in general, nonetheless does not seem to be keeping up with the progress made in oncohematology, or in the world of adult cancer. But the story behind the maintenance therapy adopted in the EpSSG protocol goes to show that a bit of creative spirit sometimes helps. Medical researchers can sometimes craft a good result from an innovative and original use of existing medicines. Bright ideas sometimes produce great results. In the present case, a good use of the available drugs also gave rise to a therapy that was well-tolerated and suitable for administering to outpatients, and potentially even orally: features that greatly improve patients' quality of life. This was a classic case of low drug doses working better than high ones.
Of course, the researcher has to follow precise methodologic pathways, which have become increasingly complicated over time. This raises a third important point emerging from EpSSG RMS 2005. The results come 20 years after starting the first trial that demonstrated the efficacy of vinorelbine and more than 13 years after the first patient was enrolled in the EpSSG RMS 2005 protocol. This has taken too long. For rare tumors, it takes too long a time to enroll a sample large enough to satisfy the demands of classical statistical methods. We must develop more flexible research methods. But we also need to make the methodologic, regulatory and administrative requirements more straightforward, because setting up a new clinical trial is extremely complicated and costly.
Given the results of EpSSG RMS 2005, what should the next research steps be? The answer depends partly on how we interpret the improvement in survival associated with the maintenance therapy. In principle, it may stem from having extended the total duration of the treatment, from the effect of the extra drugs, or from a combination of these 2 factors. Simply prolonging chemotherapy may have a role. Different protocols developed over the years have gradually reduced the total duration of treatments from the original 2 years without apparently impairing the results, but analyses on particular subgroups of patients would suggest a better outcome for patients treated for longer. 28 On the other hand, the better outcome achieved with the maintenance therapy may relate to the drugs involved, i.e., vinorelbine and/or low-dose cyclophosphamide. Their combined effect may elicit an anti-angiogenic mechanism, killing tumor cells resistant to the standard therapy.
After the first study in Milan, the efficacy of vinorelbine as a single agent was confirmed by a COG phase II trial that achieved a positive response in 4 out of 11 cases (Table 1) . 29 Taken together, in the 2 series given vinorelbine alone, 10 out of 23 patients responded, a response rate of 43%. To put this percentage in perspective, the irinotecan-vincristine regimen (the most active combination tested in a window setting in metastatic rhabdomyosarcoma, with a response rate of 70%) 30 has achieved response rates in refractory disease of 25%-37% (and 11%-16% for irinotecan alone). 31 After the Italian pilot study, the vinorelbine and low-dose cyclophosphamide combination was further investigated by the French cooperative group, which reported 4 complete remissions and 18 partial remissions among 50 cases of refractory rhabdomyosarcoma in 2012 (Table 1 ). 32 The response rate from the 2 series treated with the combination therapy was 37% (25 responses out of 67 cases), so the response rate for the combination would seem to be no better than for vinorelbine alone. Clearly, the number of patients involved is still too small for any conclusions to be drawn on the relative contributions of the 2 drugs.
Both the above hypotheses-whether survival improves due to a longer treatment or to the efficacy of the extra drugs, and vinorelbine in particular-need to be investigated further.
As regards the duration of the treatment, we need to explore (preferably in randomized trials) the effects of a longer maintenance therapy (e.g., 12 months instead of 6 of vinorelbine and cyclophosphamide); the effects of this maintenance therapy in other unfavorable subgroups of patients (e.g., those with metastatic disease at diagnosis); and the effects of maintenance therapy with different drugs (the German group used trofosfamide, etoposide, and idarubicin, for instance). The next EpSSG study will try to investigate some of these options.
If we attribute the value of the maintenance therapy to the efficacy of vinorelbine, we could try using more vinorelbine, adding it to the induction therapy, thus trying to find more effective uses for the available standard chemotherapy agents; in this case, by increasing the chemotherapy's intensity and adopting a shorter interval than the usual 3 weeks of the IVA regimen, for instance. This strategy is being used at the Istituto Nazionale dei Tumori in Milan to test the efficacy and tolerability of a regimen called VIVA (vinorelbine, ifosfamide, vincristine, and actinomycin-D), which adds vinorelbine on days 8 and 15 of each IVA cycle (Figure 2 ). This schedule means that more effective drugs are administered during induction, chemotherapy is given every week, and vinorelbine is used more intensively. Vinorelbine can also be given orally, making the regimen more tolerable. The first patients have been treated with the VIVA regimen in Milan, but more cases and further investigations are needed to establish the correct dose of vinorelbine.
This new regimen might be included in the next EpSSG study on rhabdomyosarcoma, as efforts to find new, effective agents to add to the gold standard IVA need to continue. The ideal additional drug should have a different mechanism of action from the classic antitumor activity of the standard drugs. Agents targeting specific genetic abnormalities of tumor cells would be ideal, but finding new biological agents in rhabdomyosarcoma is a challenge. In fact, targeted agents have not had the same impact on the pediatric population as on adult patients, due partly to the smaller numbers of pediatric cancer patients, but also to legal restrictions that make it more difficult to develop new drugs for children and orphan diseases. While we wait for promising new biological agents to become available for children with rhabdomyosarcoma, adding effective drugs like vinorelbine (and others such as irinotecan) to standard IVA is a simple way to try to improve their treatment, especially if the dose-density approach (giving chemotherapy over a shorter period of time) can be used.
Gaining a better understanding of the biological mechanisms behind the pathogenesis of rhabdomyosarcoma is the first step towards identifying new specific targets and novel biological agents. This overview on rhabdomyosarcoma gives us the opportunity to comment on a study published by our group in September on age-related biological differences in rhabdomyosarcoma. 33 This is an important matter because rhabdomyosarcoma outcomes depend on numerous prognostic variables, including histologic subtype, primary tumor site and size, lymph node involvement, and distant metastasis, 4 but also age, which strongly influences survival. 34 To give an idea, the EUROCARE-5 study reported a 66.6% 5-year OS for children (0-14 years old), as opposed to 39.6% for adolescents (15-19 years old) and 36.4% for 20-to 39-year-olds. 35 There are probably several reasons why the outcome is particularly dismal for adults with rhabdomyosarcoma, [36] [37] [38] including differences in their clinical management vis-à-vis children. They may not be referred to expert centers and included in clinical trials, for instance, and they may not receive the best possible treatments. [39] [40] [41] There could be biological differences involved, with rhabdomyosarcoma arising in older people being intrinsically more aggressive. Our knowledge of the complex genomic landscape of pediatric RMS is improving all the time, 4 but there is still a shortage of information and not enough research on the biology of rhabdomyosarcoma in adults. At the Istituto Nazionale dei Tumori, we recently completed a first set of analyses on 49 patients with rhabdomyosarcoma, 28 of them children (0-14 years old) and 21 adolescents and young adults (AYA) from 15 to 35 years old. MicroRNA analysis identified age-specific variables, i.e., miR-223 was overexpressed and miR-431 was downregulated in AYA. Correlating with gene expression profiling showed that miR-223 was associated with an upregulation of epithelial mesenchymal translation and inflammatory pathways, while miR-431 was associated with myogenic differentiation and muscle metabolism. Gene expression profiling and immunohistochemistry revealed characteristic features suggesting a role of immune cells in sustaining tumor growth that might modulate the aggressiveness of rhabdomyosarcoma in AYA. 33 These findings justify further investigations to confirm age-related differences in microenvironmental signal modulation and the role of immune contexture in tumor development. They also represent a first important step towards expanding what we know about rhabdomyosarcoma biology in relation to a patient's age, and possibly finding tailored therapeutic approaches in the future: another way to improve the outcome for patients with rhabdomyosarcoma.
